On April 24, the Food and Drug Administration announced a series of regulatory actions to accelerate the development of serotonin-2A agonists — psilocybin, MDMA, ibogaine, and related compounds — for the treatment of serious mental illness. This was not a clinical trial. It was a regulatory decision about the pathway through which these drugs will reach patients. The distinction matters more than the announcement suggested.
The mechanism the FDA chose is accelerated approval. Under standard approval, a drug must demonstrate efficacy through clinical outcomes — patients getting measurably better on defined measures. Under accelerated approval, a drug can be cleared based on a surrogate endpoint: a biomarker or intermediate measure that is reasonably likely to predict clinical benefit. The full evidence of actual clinical benefit is collected after the drug is already in use. Post-marketing confirmatory trials are required, but the drug reaches patients while those trials are still running.
Accelerated approval was created for HIV medications in the early 1990s, when the need was urgent and the alternative was patients dying while waiting for complete data. It has since been used extensively in oncology, where the same logic applies. The FDA has also used it in psychiatry — and that history is more complicated.
Aduhelm, the Alzheimer’s drug approved via accelerated approval in 2021, was cleared based on its ability to reduce amyloid plaques in the brain, a surrogate endpoint. The clinical trials that followed did not consistently show that reduced amyloid translated into meaningful improvement in patient function or cognition. The drug was priced at $56,000 per year at launch. Medicare initially refused to cover it for most patients. The manufacturer eventually withdrew it from the market in 2024, after the confirmatory trial produced results the agency found insufficient. The episode prompted a congressional investigation into how the FDA makes accelerated approval decisions and how it enforces the post-marketing trial requirement when results disappoint.
Psychedelic therapies present a distinct challenge for surrogate endpoint selection. Unlike a protein biomarker or an imaging finding, the proposed mechanisms of psychedelic action — neuroplasticity, default mode network disruption, mystical experience — are not easily reduced to a measurable intermediate. What the FDA has accepted as a reasonable surrogate for clinical benefit in this context has not been publicly specified in the April 24 announcement. That specification will determine whether accelerated approval in this category is a legitimate expedited pathway or a structural shortcut whose consequences patients will live with before the confirmatory data arrives.
The underlying therapeutic promise of these compounds is real and supported by a growing evidence base. MAPS has conducted genuine phase 3 trials. The Johns Hopkins psilocybin research has produced results worth taking seriously. The question is not whether psychedelic therapies have potential. It is whether the accelerated approval mechanism, applied to a category where surrogate endpoints are poorly defined and the set and setting variables of clinical trials are almost impossible to replicate in commercial practice, will produce the same pattern that played out with Aduhelm: wide availability, high prices, insufficient post-market evidence, and eventual reconsideration after patients have already been exposed.
What to watch: the FDA guidance document specifying what surrogate endpoints it will accept for psychedelic accelerated approvals, and the post-marketing trial requirements attached to the first drugs that clear this pathway. Those details will tell you what the April 24 announcement actually means.
American Life is independent analysis.
